Deals
-
J&J bets $2.2B on Ollin’s vision loss drug
The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.
By Delilah Alvarado • Nov. 16, 2026 -
Lilly adds to buyout streak with $1.5B purchase of startup Calytrix
Lilly’s 15th announced acquisition this year — by far the most in the biopharmaceutical sector — centers around a precision therapy for rare blood disorders known as myeloproliferative neoplasms.
By Ben Fidler • Nov. 16, 2026 -
Obesity drugs
Blackstone bets $1.5B on Pfizer’s obesity drug
The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.
By Jonathan Gardner • Nov. 12, 2026 -
Argenx to buy peptide platform in potentially billion-dollar deal
For $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious immune-mediated diseases.
By Jacob Bell • Nov. 9, 2026 -
Karyopharm, deep in debt, to sell itself in bankruptcy
The parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which recently cut a forbearance deal to push off debt payments.
By Jonathan Gardner • Nov. 2, 2026 -
Ferring to acquire next-gen IVF startup Gameto for up to $1.4B
The buyout hands Ferring rights to a technology capable of simplifying the lengthy and burdensome process of in vitro fertilization.
By Delilah Alvarado • Updated Oct. 28, 2026 -
Merck KGaA bets on RNAi with $1.3B Silence buyout
The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.
By Jonathan Gardner • Oct. 19, 2026 -
News roundup
Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study
Roche is paying Hansoh $400 million up front in a broad deal involving several ADCs. Elsewhere, another top investor formed a China-focused fund and Ultragenyx sold a second review voucher.
By BioPharma Dive staff • Oct. 19, 2026 -
This week in charts
This week in charts: Moderna’s massive stock run
The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.
By Delilah Alvarado • Oct. 16, 2026 -
Belgian startup revives Galapagos CAR-T research
Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.
By Jonathan Gardner • Oct. 15, 2026 -
Another Paragon spinout goes public through reverse merger
One lawyer involved noted how it's yet another example of Paragon and key investor Fairmount — which have helped transform the reputation for reverse mergers — quickly executing on a complicated deal.
By Jacob Bell • Oct. 13, 2026 -
China competition
Roche extends China deal streak with $1B pact for RNAi obesity drug
An alliance with Rona Therapeutics adds to a particularly active stretch for Roche and makes the company the latest to bet on medicines that can lower levels of “visceral” fat.
By Jonathan Gardner • Oct. 13, 2026 -
Viatris boosts pain drug portfolio with $1.7B buyout of Pacira
The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent protection. Viatris vowed to use its “intellectual property expertise” to sustain sales.
By Jonathan Gardner • Oct. 8, 2026 -
Emerging biotech
In the hunt for reverse merger targets, Caribou could be prized game
The struggling cell therapy developer is exploring strategic alternatives, which, among other characteristics, make it a likely candidate to receive reverse merger interest.
By Jacob Bell • Oct. 8, 2026 -
GE HealthCare to acquire Sofie Biosciences for $945M
The purchase expands GE HealthCare’s radiopharmaceutical capabilities, helping manufacture and distribute time-sensitive drugs used in PET imaging.
By Susan Kelly • Oct. 6, 2026 -
Shionogi pays $2B to acquire a rare disease startup
The acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a marketed treatment for two inherited conditions.
By Jonathan Gardner • Oct. 5, 2026 -
News roundup
Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug
The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and CSL cut licensing deals and the FDA endorsed broader use of a Lilly medicine.
By Ben Fidler • Oct. 5, 2026 -
Sanofi, Regeneron broaden alliance to find their next Dupixent
The deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after the same targets as their blockbuster anti-inflammation agent.
By Jacob Bell • Oct. 1, 2026 -
Obesity drugs
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill
The deal, which hands Novo a challenger to Lilly’s market-leading Zepbound, comes as the Danish drugmaker looks to calm investor fears about its future.
By Jonathan Gardner • Sept. 29, 2026 -
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.
By Ben Fidler • Sept. 29, 2026 -
Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’
Worth $1.65 billion up front, the deal combines two large pipelines and manufacturing networks, helping Telix potentially “corner the industry” for radiopharmaceuticals, one analyst wrote.
By Ben Fidler • Sept. 21, 2026 -
Obesity drugs
Novo partners with Orbis, deepening investment in oral peptide drugs
The potentially $1.4 billion alliance will see the two companies collaborate on “macrocycles” that could yield oral treatments for cardiometabolic diseases.
By Jonathan Gardner • Sept. 17, 2026 -
Novartis to pay $125M for blood-brain barrier crossing platform
Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three candidates that the startup says have “best-in-class” potential.
By Delilah Alvarado • Sept. 16, 2026 -
This week in charts
This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree
RA Capital has already participated in four biotech financings in September. Meanwhile, Janus Henderson has been the year's most prolific backer of biotech reverse merger deals, according to Gilmartin Group.
By Jacob Bell • Sept. 11, 2026 -
Deep Dive
A booming business on Wall Street would love more biotechs to quietly die
Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality shell companies to meet the demand.
By Jacob Bell • Sept. 10, 2026